Doctors explain how Moderna's melanoma mRNA vaccine could fight deadliest form of skin cancer
August 19, 2026 / 9:03 PM EDT / CBS News
TL;DR
- Moderna's experimental melanoma vaccine uses mRNA technology and is personalized to each patient's tumor.
- The vaccine, used alongside Merck's Keytruda immunotherapy, aims to prevent the recurrence or spread of advanced melanoma.
- The treatment works by removing cancer's ability to hide from the immune system and then training the immune system to attack cancer cells.
- A Phase 3 trial showed statistically significant and clinically meaningful improvement in keeping patients cancer-free longer.
- Melanoma is the fifth most commonly diagnosed cancer in the U.S., with a significant number of annual deaths.